Pharmafile Logo

Research conducted for Johnson and Johnson published in scientific journal

April 17, 2024 |  

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

- PMLiVE

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.

The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.

For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.

Find out more and read the full publication. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Research Partnership is on the rise

Research Partnership ranks 12th in fastest growing UK market research agency league  tables

What does the future hold for Light-chain Amyloidosis?

Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...

Webcast: Securing a future for telehealth with immersive market research insights

Research Partnership investigate the current landscape, the challenges to adoption and the future for telehealth.

MAKING THE FIRST YEAR MATTER

*Mind+Matter closes its first year of business celebrating more than £4 million of new business wins in the UK *The global agency launched in Jan 21 has also been awarded...

Breaking the silence: It’s time to talk about the menopause

Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change.

News:

Senior Analytics Specialist joins Research Partnership

ASHFIELD HEALTH LAUNCHES HEALTH INTELLIGENCE PLATFORM, GRAVITY.AI

Dynamic data-driven solution unlocks deeper insights and powers stronger omnichannel experiences.

Article:

All change – how untangling human behaviour can encourage better health

Webcast:

Understanding changing digital behaviours: Insights needed for an effective omnichannel strategy

News:

Therapy Watch COVID-19 tracker